Here, we show that FXN levels are upregulated after acute retinal ischemia/reperfusion with a peak at 24 hours of reperfusion. To our knowledge, this is the first study showing an involvement of FXN in the response to ischemia/reperfusion in the central nervous system in vivo. Our findings are in agreement with other studies reporting FXN upregulation in response to hypoxic stress in vitro.
24,25 Upregulated FXN expression is also found in several tumor cell lines in response to hypoxic stress and promotes tumor cell survival and progression.
25 The role of increased FXN levels following retinal ischemia is not clear, but could be part of a response mechanism aimed to overcome lesion-induced iron dysregulation and increased oxidative stress. Recently, an increase in FXN levels was found to have a cardioprotective effect against ischemia/reperfusion.
26 In order to evaluate the effect of increased FXN on neuronal survival following acute retinal ischemia/reperfusion in vivo, we used a conditional mouse model overexpressing FXN under the control of a ubiquitous active promoter. Mice constitutively expressing the full-length hFXN cDNA have been already described and do not show any signs of ataxia or other obvious abnormalities.
27 High levels of FXN were revealed in all major organs affected in FRDA, including the pancreas, brain, skeletal muscle, and the heart.
28 In our mouse model, we found that prelesion overexpression of hFXN and not lesion-induced expression leads to enhanced neuronal cell survival in the retina after acute ischemia/reperfusion in vivo. Our results are in support of other studies showing that FXN delivered prelesion is neuroprotective in different brain regions.
3,16 Frataxin-mediated neuroprotection might involve a preconditioning effect and an induction of long-lasting retinal ischemic tolerance, as has been shown after treatment with the iron chelator deferroxamine.
29 As already mentioned, FXN plays an important role in mitochondrial iron homeostasis.
12,13 In wild-type mice, we found increased levels of FXN mature protein after lesion, whereas the precursor form was not elevated. In contrast, although levels of the precursor protein were significantly increased in transgenic as compared to wild-type mice, the mature protein was not changed after lesion. This might suggest that in wild-type mice FXN is converted into mature protein after lesion, whereas in transgenic mice maximum levels of the mature protein have already been reached before lesion. Therefore, no further increase takes place after lesion, and the precursor form accumulates in the cell. The reason for the lack of increase of FXN's mature form after ischemia in transgenic animals, compared to wild-type, is not clear and needs to be further evaluated. Importantly, translation of FXN mRNA into protein as well as enzyme maturation has been shown to be tightly regulated.
30